[CAS NO. 1391054-02-6]  Vigabatrinhydrochloride

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1391054-02-6]

Fulfillment
Catalog
AS321025
Brand
Arctom Scientific
CAS
1391054-02-6

DESCRIPTION [1391054-02-6]

Overview

MDLMFCD28142357
Molecular Weight165.62
Molecular FormulaC6H12ClNO2
SMILESC=CC(N)CCC(O)=O.Cl

For research use only. We do not sell to patients.


Summary

Vigabatrin hydrochloride (γ-Vinyl-GABA hydrochloride), a inhibitory neurotransmitter GABA vinyl-derivative, is an orally active and irreversible GABA transaminase inhibitor. Vigabatrin hydrochloride is an antiepileptic agent, which acts by increasing GABA levels in the brain by inhibiting the catabolism of GABA by GABA transaminase [1] [2] [3] .


In Vitro

A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT03003143 Seoul National University Hospital
Autoimmune Encephalopathy
November 2016 Not Applicable
NCT04062890 University of Arizona|Arizona Department of Health Services
Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension
December 15, 2019 Phase 2
NCT04772547 University of Florida|Yale University|Thomas Jefferson University|American Heart Association
Status Epilepticus, Electrographic|Coma
September 22, 2021 Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)


Solvent & Solubility

In Vitro:

H 2 O : 33.33 mg/mL ( 201.24 mM ; Need ultrasonic)

DMSO : 27.5 mg/mL ( 166.04 mM ; Need ultrasonic and warming)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.0379 mL 30.1896 mL 60.3792 mL
5 mM 1.2076 mL 6.0379 mL 12.0758 mL
10 mM 0.6038 mL 3.0190 mL 6.0379 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 10 mg/mL (60.38 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (15.09 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (15.09 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (15.09 mM); Clear solution

* All of the co-solvents are available by MCE.